Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

324

HTML

2698

Figures (1-4)

220

Tables (1-2)

171

Sum=3413

Jun 21, 2007 (publication date) through Nov 8, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jun 21, 2007; 13(23): 3164-3170
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3164

Full Size Figure Download Figure

Figure 2 Increased uptake of ¹¹¹Indium labeled octreotide in the right hepatic lobe. Somatostatin receptor positive scan.

Citation: Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170
URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3164.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3164